Home > Drugs A – Z > Sevelamer (By mouth)

Sevelamer (By mouth)

Lowers the amount of phosphorus in blood of patients receiving kidney dialysis.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Sevelamer is used to treat hyperphosphatemia (too much phosphate in the blood) in patients with chronic kidney disease who are on dialysis. This medicine is available only with your doctor's prescription… Read more
Brand names include
Renagel, Renvela
Drug classes About this
Phosphate Binder

What works? Research summarized

Evidence reviews

Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients

BACKGROUND: Accelerated cardiovascular calcification often occurs in patients with cardiovascular disease who are on hemodialysis. We performed a meta-analysis to compare the effects of sevelamer hydrochloride and calcium-based phosphate binders on coronary artery calcification, C-reactive protein, alkaline phosphatase and intact parathyroid hormone in patients undergoing hemodialysis.

Systematic review of the clinical efficacy and safety of sevelamer in dialysis patients

BACKGROUND: The relative effectiveness and safety of sevelamer for treatment of hyperphosphataemia in dialysis patients is uncertain, as compared with calcium-based phosphate binders.

Hyperphosphataemia in Chronic Kidney Disease: Management of Hyperphosphataemia in Patients with Stage 4 or 5 Chronic Kidney Disease

Chronic kidney disease (CKD) describes abnormal kidney function and/or structure. It is common and often exists together with other conditions, such as cardiovascular disease and diabetes.

See all (9)

Summaries for consumers

Sucroferric oxyhydroxide (Velphoro) for chronic kidney disease: Overview

Sucroferric oxyhydroxide (trade name: Velphoro) has been approved in Germany since August 2014 for treating chronic kidney disease in adults by regulating phosphate levels.

Phosphate binders for preventing and treating bone disease in chronic kidney disease patients

People with chronic kidney disease (CKD) develop impaired excretion of the dietary phosphorus. This results in a condition known as mineral and bone disorder in chronic kidney disease (CKD‐MBD). CKD‐MBD is characterized by high bone turnover, increased musculoskeletal morbidity including bone pain and muscle weakness, and vascular calcification which may contribute to the high incidence of cardiovascular disease and associated deaths. Several agents such as phosphate binders, vitamin D compounds, and calcimimetics are widely used to slow the development and progression of CKD‐MBD complications.

Interventions for metabolic bone disease in children with chronic kidney disease

Chronic kidney disease (CKD) resulting in reduced kidney function and the need for dialysis and kidney transplant is associated with abnormalities in serum calcium and phosphorus levels leading to high levels of the parathyroid hormone (PTH) and to bone disease. This may result in bone deformities, bone pain, fractures and reduced growth rates. Commonly used treatments (vitamin D compounds and phosphate binders) aim to prevent or correct these outcomes. However, these treatments may raise levels of blood calcium, allow calcium and phosphorus deposition in blood vessels and lead to early cardiovascular disease, which is known to be a problem in adults with CKD.

PubMed Health Blog...

read all...